Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 13Recurrence 4Myelodysplastic Syndromes 4Leukemia, Biphenotypic, Acute 4Leukemia, Hairy Cell 3Sarcoma, Myeloid 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Blast Crisis 2Targeted Therapy 1Myeloproliferative Disorders 1Myasthenia Gravis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 11Azacitidine 10fludarabine 9Whole-Body Irradiation 9Specimen Handling 9Biopsy 9Stem Cell Transplantation 8Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Tacrolimus 6Cytarabine 6X-Rays 5Hematopoietic Stem Cell Transplantation 5Decitabine 4Cyclosporine 4Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Magnetic Resonance Spectroscopy 3Injections 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Cyclosporins 3Busulfan 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3ruxolitinib 2pegylated granulocyte colony-stimulating factor 2olutasidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Chronic × Cladribine × Clear all
NCT04375631 2026-03-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutchinson Cancer Center

Phase 1 Recruiting
120 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
324 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡